(胃癌靶向治疗)Molecular targeted therapy for advanced gastric.pdf

REVIEW Korean J Intern Med 2013;28:149-155 /10.3904/kjim.2049 Molecular targeted therapy for advanced gastric cancer Jong Gwang Kim Department of Internal Medicine, Although medical treatment has been shown to improve quality of life and pro- Kyungpook National University long survival, no significant progress has been made in the treatment of advanced School of Medicine, Daegu, Korea gastric cancer (AGC) within the last two decades. Thus, the optimum standard first-line chemotherapy regimen for AGC remains debatable, and most responses to chemotherapy are partial and of short duration; the median survival is approx- imately 7 to 11 months, and survival at 2 years is exceptionally 10%. Recently, remarkable progress in tumor biology has led to the development of new agents that target critical aspects of oncogenic pathways. For AGC, many molecular Received: January 3, 2013 targeting agents have been evaluated in international randomized studies, and Accepted: February 6, 2013 trastuzumab, an anti-HER-2 monoclonal antibody, has shown antitumor activity Correspondence to against HER-2-positive AGC. However, this benefit is limited to only ~20% of pa- Jong Gwang Kim, M.D. tients with AGC (patients with HER-2-positive AGC). Therefore, there remains a Department of Internal critical need for both the development of more effective agents and the identifica- Medicine, Kyungpook National University School of Medicine, tion of molecular predictive and prognostic markers to select those patients who 680 Gukchaebosang-ro, Jung-gu, will benefit most from specific chemotherapeutic regimens and targeted